

亞東紀念醫院

Cervical Cancer

化學治療處方集

2008-08 制定

最近修改日期：2014-05

Cervical Cancer 化學治療處方參考集

2008-08 制定 2014-05 最後修定

【CCRT】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Cisplatin 40 mg/m² or Carboplatin (100 mg/m² or AUC =2) in N/S 250ml IV drip 2 hrs, weekly, concomitant with radiotherapy

References :

1. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.
2. Katanyoo K, Tangjitgamol S, Chongthanakorn M, et al. Treatment outcomes of concurrent weekly carboplatin with radiation therapy in locally advanced cervical cancer patients. Gynecol Oncol 2011;123:571-6.
3. Higgins RV, Naumann WR, Hall JB, et al. Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. Gynecol Oncol 2003;89:499-503.

【POB】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Cisplatin 50 mg/m² in N/S 250 ml iv drip 2 hrs D1
Vincristine 1 mg/m² in N/S 100 ml iv drip 30 mins. D1
Bleomycin 25 mg/m² in D5W 500cc iv drip 24 hours D1-3
Every 10 days * 3 cycles

References :

1. Sardi JE, Giaroli A, Sananes C, et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol 1997;67:61-9.

Cervical Cancer 化學治療處方參考集

2008-08 制定 2014-05 最後修定

【Cisplatin + topotecan】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Topotecan 0.75 mg/m² in N/S 100ml iv drip 30 mins D1-D3

Cisplatin 50 mg/m² in N/S 250ml iv drip 2-3 hrs D1

or Carboplatin (AUC 5-6, Ccr < 60 or Cisplatin intolerance) in N/S 250 ml iv drip 1 hr D1

Every 21 days

References:

1. Long HJ III, Bundy BN, Grendys EC Jr, et al: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626-33.

【Cisplatin + ifosfamide】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Cisplatin 50 mg/m² in N/S 250cc iv drip 2 hours D1

Ifosfamide 5g/m² over 24 hours D1

Mesna 6 g/m² during ifosfamide infusion and the following 12 hours

Every 21 days

References :

1. Bloss JD, Blessing JA, Behrens BC, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2002;20:1832-7.

Cervical Cancer 化學治療處方參考集

2008-08 制定 2014-05 最後修定

【Cisplatin + weekly HDFL】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Cisplatin 45 mg/m² in N/S 250cc iv drip 2 hours D1, D8

5-FU 2600 mg/m² + Leucovorin 300 mg/m² in D5W or N/S 350cc
iv drip 24 hours D1, D8, D15

Every 28 days

References :

1. Hsiao SM, Chen CA, Hsu C, et al. Weekly cisplatin, infusional high-dose 5-fluorouracil and leucovorin for advanced, recurrent and metastatic cervical carcinoma. Anticancer Res 2008;28:1887-91.

【Cisplatin + paclitaxel】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Paclitaxel 135 mg/m² over 24 hours or 175 mg/m² over 3 hours D1

Cisplatin 50 mg/m² in N/S 250cc iv drip 2 hours D1

Every 21 days

Paclitaxel(健保不給付)

References :

1. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649-55.
2. Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:734-43.

Cervical Cancer 化學治療處方參考集

2008-08 制定 2014-05 最後修定

【Cisplatin + gemcitabine】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Gemcitabine 1,000 mg/m² D1 and D8

Cisplatin 50 mg/m² in N/S 250cc iv drip 2 hours D1

Every 3 weeks

Gemcitabine (健保不給付)

References :

1. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649-55.

【Topotecan + paclitaxel】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Paclitaxel 175 mg/m² over 3 hours D1

Topotecan 0.75 mg/m² in N/S 100ml iv drip 30 mins D1-D3

Every 21 days

Paclitaxel 健保不給付

References :

1. Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:734-43.

Cervical Cancer 化學治療處方參考集

2008-08 制定 2014-05 最後修定

【Cisplatin + paclitaxel + bevacizumab】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative

Cisplatin 50 mg/m² in N/S 250cc iv drip 2 hours D1

Paclitaxel 135 mg/m² over 24 hours or 175 mg/m² over 3 hours D1

Bevacizumab 15 mg/m² D1

Every 21 days

Paclitaxel, bevacizumab(健保不給付)

References :

1. Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:734-43.